Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is crucial for tumor surveillance and preferentially induces apoptosis in cancer cells.
• The TRAIL receptor, DR5, is a key target for antibody-mediated cancer therapies.
• Current antibody therapies aim to leverage immune responses for tumor elimination.

Purpose of the Study:

• To investigate the efficacy of a monoclonal antibody (mAb) targeting the mouse TRAIL receptor, DR5, in cancer therapy.
• To evaluate the antibody's ability to induce antitumor effects and immune memory.
• To assess the safety and therapeutic potential of anti-DR5 mAb in vivo.

Main Methods:

• Development and administration of an agonistic anti-DR5 mAb in mouse models.
• Assessment of in vivo antitumor activity against TRAIL-sensitive tumors.
• Evaluation of inhibition of experimental and spontaneous tumor metastases.
• Analysis of innate immune cell recruitment and T cell-mediated immunity induction.

Main Results:

• The anti-DR5 mAb demonstrated potent antitumor effects in vivo against TRAIL-sensitive tumor cells.
• Administration of the antibody inhibited both experimental and spontaneous tumor metastases.
• Immune cell recruitment by the anti-DR5 mAb led to tumor rejection and evoked tumor-specific T cell immunity.
• This T cell immunity could eradicate TRAIL-resistant tumor variants and confer long-term protection.

Conclusions:

• Antibody-based therapy targeting DR5 is an effective strategy for eliminating TRAIL-sensitive tumors.
• This approach induces robust tumor-specific T cell memory, providing protection against tumor recurrence.
• The anti-DR5 mAb therapy offers a promising avenue for durable cancer treatment with minimal systemic toxicity.